本帖最后由 老马 于 2013-3-13 13:43 编辑
" v. S/ P2 j6 O/ w! \/ k% Z) V
( ]& h, T5 S" ^$ r1 o) M健择（吉西他滨）+顺铂+阿瓦斯汀
+ ^0 o5 h1 w; b5 }& l! ]' _4 y Gemzar +Cisplatin + Avastin
X' a. H$ p, P/ Nhttp://annonc.oxfordjournals.org/content/21/9/1804.full
# r8 ^. A. Y3 q9 SOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 n. @* r0 g2 t8 s+ I6 mPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 h \' _' S4 yResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 D0 N0 L2 U8 y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 763)
. N! T4 A- R4 g( C2 {华为网盘附件：
. m* ~+ w( t' O/ z【华为网盘】ava.JPG
' X5 I" h$ I5 Y- v, T/ M |
显身卡
